Skip to main content
This block is broken or missing. You may be missing content or you might need to enable the original module.
Home
  • English
  • Svenska
  • Français
  • Deutsch
  • Español
  • Italiano
  • Português

Main sub menu

  • Investors
    • Investor relations
    • Rights Issue 2020
    • Annual Report 2019
    • The share
    • Financial news
    • Financials
    • Corporate governance
  • Careers
    • Working at Recipharm
    • The Recipharm story
    • Meet our employees
    • Current vacancies
  • Contact
    • Contact us
    • Development services contacts
    • Manufacturing services contacts
    • Locations
      • France
        • Fontaine
        • Kaysersberg
        • Monts
        • Pessac
      • Germany
        • Monheim
        • Wasserburg
        • Zwickau
      • India
        • Bengaluru
        • Karnal / Paonta Sahib
      • Israel
        • Ness Ziona
      • Italy
        • Brescia
        • Lainate
        • Masate
        • Paderno Dugnano
        • Pianezza
      • Portugal
        • Odivelas
        • Queluz
      • Spain
        • Parets
        • Leganés
      • Sweden
        • Höganäs
        • Stockholm city (HQ)
        • Karlskoga
        • Solna
        • Stockholm
        • Strängnäs
        • Uppsala
        • Uppsala Development
      • UK
        • Ashton
        • Cramlington
        • Holmes Chapel
        • Queenborough
        • King’s Lynn
      • USA
        • Research Triangle Park

Main navigation

  • Development
    • Drug substance
    • Drug product
    • Analytical chemistry
    • Clinical trial material (CTM)
  • Manufacturing
    • Solids
    • Semi-solids
    • Liquids
    • Inhalation
    • Injectables
    • Ophthalmics
  • Solutions
    • Recipharm Analytical Solutions™
    • Recipharm Inhalation Solutions™
    • Recipharm Pathway to Clinic®
    • Serialisation
  • Bespak
  • Learn
  • Press & events
    • Press
    • Events
    • Reports
    • Insights
  • Our story
    • Recipharm in brief
    • Business model
    • Business overview
    • Sustainability
    • Company history

Investor relations

Financial news

Financial information

  • Financial press
  • Financial events
  • Financial reports

Investors

  • Investor relations
  • Rights Issue 2020
  • Annual Report 2019
  • The share
  • Financial news
  • Financials
  • Corporate governance
Contact

Contact details

ir@recipharm.com
+46 8 602 52 00

Subscribe

Footer menu

  • Privacy policy
  • Cookies
  • Website terms
© 2020 Recipharm AB (publ). All rights reserved Stormfors Digitalbyrå